Status:
TERMINATED
A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
Lead Sponsor:
Pfizer
Conditions:
Hyperlipidemia
Dyslipidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination...
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- Specific LDL-C levels based on CHD risk after a six-week washout period.
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
- Subjects requiring systemic steroids
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study.
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
1784 Patients enrolled
Trial Details
Trial ID
NCT00267267
Start Date
January 1 2006
End Date
January 1 2007
Last Update
December 10 2007
Active Locations (123)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209-7802
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35235
3
Pfizer Investigational Site
Chandler, Arizona, United States, 85224
4
Pfizer Investigational Site
Mesa, Arizona, United States, 85201